NCT04169711View on ClinicalTrials.gov

Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

January 24, 2022

Study Completion Date

July 22, 2022

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

ARO-HIF2

Multiple doses of ARO-HIF2 by intravenous infusion

Trial Locations (5)

37232

Research Site 4, Nashville

75390

Research Site 5, Dallas

77030

Research Site 6, Houston

80045

Research Site 1, Aurora

89169

Research Site 2, Las Vegas

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY